An Observational Study to Learn More About How Safe Rivaroxaban is And How Well it Works in Children With Congenital Heart Disease Who Had a Heart Surgery Called the Fontan Procedure

Congenital Heart Disease Clinical Trial

Official title:

Special Drug Use Investigation of Rivaroxaban in Pediatric Patients With Congenital Heart Disease (CHD) Who Had Undergone the Fontan Procedure

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06193863
• Other study ID #: 22468
• Status: Not yet recruiting
• Start date: May 31, 2024
• Est. completion date: December 31, 2026

Study information

• Verified date: May 2024
• Source: Bayer
• Contact: Bayer Clinical Trials Contact
• Phone: (+)1-888-84 22937
• Email: clinical-trials-contact[@]bayer.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This is an observational study in which the data from children with congenital heart disease will be collected and studied. These children will include those who are prescribed rivaroxaban by their doctors after a heart surgery called the Fontan procedure.

Congenital heart disease (CHD) is a heart problem that some children are born with. It sometimes requires a surgery called the Fontan procedure to improve the blood flow in the body. The Fontan procedure can increase the risk of the formation of blood clots in the blood vessels (called thrombosis), which might lead to death.

The study drug, rivaroxaban, is an approved treatment for preventing the formation of blood clots. It is a type of anticoagulant that prevents the blood from clotting by blocking a protein responsible for it. Rivaroxaban can increase the risk of bleeding.

A previous study suggested that the number of major bleeding episodes did not differ much while taking rivaroxaban compared to aspirin in children with CHD who had undergone the Fontan procedure. However, there is limited information available for Japanese patients.

To better understand the safety and potential risks of this drug in children, more knowledge is needed about the use of rivaroxaban in the real world.

The main purpose of this study is to learn more about the occurrence of major bleeding or non-major bleeding in children who were treated with rivaroxaban. Major bleeding is defined as a serious or life-threatening bleeding episode that can have an impact on a person's health and requires medical attention. Non-major bleeding is defined as a type of bleeding that may negatively impact a person's health if not treated.

The data will be collected from December 2023 to June 2026. Researchers will observe each participant for up to 30 days after stopping the treatment or for a maximum of 2 years.

In this study, only available data from regular health visits will be collected. No visits or tests are required as part of this study. Researchers will use the medical records or interview the children and/or their guardians during regular visits.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 50
• Est. completion date: December 31, 2026
• Est. primary completion date: June 30, 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A to 18 Years

Eligibility

Inclusion Criteria:

• Patients under the age of 18 years

• Patients diagnosed with CHD who had undergone the Fontan procedure by the investigator under routine clinical practice, and must be judged appropriate for/decided to be treated with rivaroxaban by the investigator under routine clinical practice

• Informed consent form obtained from a legal representative

Exclusion Criteria:

• Participation in an investigational program with interventions outside of routine clinical practice

• Contraindications according to the local marketing authorization

• Previous treatment with rivaroxaban

Related Conditions & MeSH terms

• Children
• Congenital Heart Disease
• Fontan Procedure
• Heart Defects, Congenital
• Heart Diseases
• Prevention of Venous Thromboembolism
• Thromboembolism
• Venous Thromboembolism

Intervention

Drug:
• Rivaroxaban (Xarelto, BAY59-7939)
At the discretion of the treating physician, based on the recommendations written in the local product information.

Locations

Country	Name	City	State
Japan	Many Locations	Multiple Locations

Sponsors (2)

Lead Sponsor	Collaborator
Bayer	Janssen Research & Development, LLC

Country where clinical trial is conducted

Japan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Occurrence of major bleeding or clinically relevant non-major bleeding		Up to 2 years
Secondary	Occurrence of any bleeding		Up to 2 years
Secondary	Occurrence of all adverse events (AEs)		Up to 2 years
Secondary	Occurrence of thrombotic events		Up to 2 years
Secondary	Descriptive summary of patient demographics/characteristics		Up to 2 years
Secondary	Dosing patterns of rivaroxaban		Up to 2 years

External Links

•   Click here for access to information about Bayer's transparency standards and Bayer studies.